This site is intended for healthcare professionals only
LoginRegister

Senores Pharma gets Philippine FDA approval for basket of 10 products

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli   |  
Senores Pharma gets Philippine FDA approval for basket of 10 products
  • whatsapp
  • Telegram

Ahmedabad: Senores Pharmaceuticals has announced that it has received marketing authorizations from the Philippine Food and Drug Administration (FDA) for a basket of 10 products across Therapies like Cardiovascular, CNS, and Pain management, etc.

This marks a significant step in the company’s strategy to expand its footprint in Southeast Asia and enhance access to affordable healthcare. The approvals provide Senores Pharmaceuticals with a strong platform to serve the Philippines.

The market size of these particular drugs in the Philippines is valued at US $23 million, underscoring the immense opportunity for growth and patient impact.

“These approvals reaffirm our commitment to delivering high-quality, affordable treatments for patients,” said Swapnil Shah, Managing Director of Senores Pharmaceuticals. “Philippines is a critical market in our regional expansion strategy, and this achievement strengthens our position as a trusted partner in advancing healthcare.”

With these regulatory endorsements, Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region.

Senores Pharmaceuticals Limited is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
The companies’ current portfolio includes 32 own ANDA and 32 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries.
The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 390 product registrations and 820+ product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).
Senores has 2 manufacturing facilities for formulations – one in Atlanta, US, which is USFDA approved and DEA/BAA compliant, and the other is in Chhatral, Ahmedabad, India, approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).
senores pharmasenores pharma newsPhilippine FDA
Ruchika Sharma
Ruchika Sharma

    Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story
    X